Participant characteristics at study entry overall by age category.

Values are median (IQR) or n (%). Significance tests for age differences are general linear models or logistic regression models for continuous and categorical variables, respectively, with age analyzed as a continuous variable. #Data unavailable for either all ESPRIT participants or for a subset of ESPRIT participants who enrolled from the Vanguard studies. *Biomarker summary statistics reflect a subset of the sample (n = 1193, 1253, and 775 for age strata, respectively). %Polypharmacy was considered as use of two or more of the following drug classes hypertensive, hyperlipidaemia, coronary artery disease, osteoporosis, or diabetes. ∧eGFR was available for participants who consented to store blood samples (n = 960, 1011, and 640 for age strata, respectively). cART = combination antiretroviral therapy. NRTI = nucleoside analog reverse transcriptase inhibitor. PI = protease inhibitor. NNRTI = non-nucleoside analog reverse transcriptase inhibitor. eGFR = estimated glomerular filtration rate. hsCRP = high-sensitivity c-reactive protein. CVD = cardiovascular disease. History of CVD event includes history of myocardial infarction, coronary artery disease surgery, or stroke.

统计指标以中位数（四分位距，IQR）或例数（百分比）表示。年龄差异的显著性检验分别采用一般线性模型（针对连续变量）与逻辑回归模型（针对分类变量），其中年龄以连续变量形式进行分析。
# 所有ESPRIT研究参与者，或从Vanguard研究招募的ESPRIT亚组参与者，均存在部分数据不可用的情况。
* 生物标志物汇总统计数据仅针对研究亚样本，按年龄分层的亚组样本量分别为1193、1253和775例。
% 多重用药定义为同时使用以下2类及以上药物：抗高血压药物、调脂药物、冠心病治疗药物、抗骨质疏松药物或降糖药物。
∧ 估算肾小球滤过率（estimated glomerular filtration rate, eGFR）数据仅适用于同意储存血液样本的参与者，按年龄分层的亚组样本量分别为960、1011和640例。
cART：联合抗反转录病毒治疗（combination antiretroviral therapy）
NRTI：核苷类反转录酶抑制剂（nucleoside analog reverse transcriptase inhibitor）
PI：蛋白酶抑制剂（protease inhibitor）
NNRTI：非核苷类反转录酶抑制剂（non-nucleoside analog reverse transcriptase inhibitor）
eGFR：估算肾小球滤过率
hsCRP：高敏C反应蛋白（high-sensitivity c-reactive protein）
CVD：心血管疾病（cardiovascular disease）
心血管疾病事件史包括心肌梗死史、冠心病手术史或脑卒中史。